Cargando…
Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
The Ebola vaccine based on Ad26.ZEBOV/MVA-BN-Filo prime-boost regimens is being evaluated in multiple clinical trials. The long-term immune response to the vaccine is unknown, including factors associated with the response and variability around the response. We analyzed data from three phase 1 tria...
Autores principales: | Pasin, Chloé, Balelli, Irene, Van Effelterre, Thierry, Bockstal, Viki, Solforosi, Laura, Prague, Mélanie, Douoguih, Macaya, Thiébaut, Rodolphe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714808/ https://www.ncbi.nlm.nih.gov/pubmed/31243126 http://dx.doi.org/10.1128/JVI.00579-19 |
Ejemplares similares
-
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Alexandre, Marie, et al.
Publicado: (2023) -
Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques
por: Keelapang, Poonsook, et al.
Publicado: (2023) -
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial
por: Lévy, Y., et al.
Publicado: (2021) -
Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein
por: Choi, Jung-ah, et al.
Publicado: (2020) -
Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates
por: Le Grand, Roger, et al.
Publicado: (2016)